A Study to Assess the Safety Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

  • STATUS
    Not Recruiting
  • End date
    Dec 9, 2022
  • participants needed
    1120
  • sponsor
    UCB Biopharma S.P.R.L.
Updated on 21 February 2021
Investigator
UCB Cares
Primary Contact
Ps0014 925 (2.0 mi away) Contact
+186 other location

Summary

This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).

Details
Condition Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Treatment Bimekizumab
Clinical Study IdentifierNCT03598790
SponsorUCB Biopharma S.P.R.L.
Last Modified on21 February 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note